Merck’s Erbitux backed by NICE for head and neck cancer
Merck | September 04, 2017
Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck. The National Institute for Health and Care Excellence has published final guidance backing the drug’s use to treat the condition, but only if the cancer started in the oral cavity and the company provides at the discount outlined in a confidential commercial access agreement with NHS England.